Following the acquisition, Astex has become a wholly owned subsidiary of SuperGen.
SuperGen plans to re-brand Astex Therapeutics as Astex Pharmaceuticals in the third quarter of 2011.
The combined company’s clinical pipeline includes seven drugs in development, four of which are currently in or entering into Phase II clinical trials and three of which are currently partnered with large pharmaceutical companies.